KRAS and pancreatic adenocarcinoma: It has been demonstrated that oncogenic KRAS mediates the reprogramming of glutamine metabolism in pancreatic adenocarcinoma cells by modifying the transcription of metabolic enzymes in a noncanonical pathway of glutamine (81).